Survodutide
Also known as: Survodutide, BI 456906
Survodutide (BI 456906) is an investigational dual agonist of the glucagon and GLP-1 receptors developed for obesity and metabolic dysfunction-associated steatohepatitis (MASH). It is administered as a once-weekly subcutaneous injection.
Last updated
Mechanism of Action
Survodutide is a synthetic peptide dual agonist that activates both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). GLP-1R activation augments glucose-dependent insulin release, delays gastric emptying, and suppresses appetite via central nervous system pathways, while GCGR activation increases hepatic fatty-acid oxidation, energy expenditure, and reduction of liver fat. This balanced co-agonism is designed to drive weight loss and resolve hepatic steatosis and inflammation, and fatty-acid acylation gives it a half-life suitable for weekly dosing.
- Half-life
- Approximately several days, supporting once-weekly administration
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Drives significant weight loss in obesity trials
- Improves liver fat content and MASH histology
- Enhances glycemic parameters
- Reduces appetite and caloric intake
- Glucagon-receptor activity raises energy expenditure
- Once-weekly dosing convenience
Potential Side Effects
- Nausea, vomiting, and diarrhea during dose escalation
- Decreased appetite
- Possible increase in heart rate
- Injection-site reactions
- Risk of hypoglycemia alongside other glucose-lowering drugs
Common Dosing
Clinical studies have explored subcutaneous doses titrated up toward roughly 6 mg once weekly. Provided for research and educational reference only, not as personal medical advice.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN 2
- History of pancreatitis
- Pregnancy and breastfeeding
- Severe gastrointestinal motility disorders
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Mazdutide
Mazdutide (IBI362) is an investigational dual agonist of the GLP-1 and glucagon receptors based on the oxyntomodulin scaffold. It is being studied for weight loss and glycemic control.
Cagrilintide
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
- View
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024
- View
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
2024
- View
Survodutide Once Weekly for the Treatment of Adults with Obesity
2026
- View
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
2022